{
  "id": 12803461,
  "title": "Pfizer's TUKYSA Gets FDA Nod For Front-Line HER2+ Breast Cancer Maintenance",
  "url": "https://urgent.news/2026/10/08/pfizers-tukysa-gets-fda-nod-for-front-line-her2-breast-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T05:01:27.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/pfizers-tukysa-gets-fda-nod-front-line-her2-breast-cancer-maintenance"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration (FDA) approved TUKYSA in combination with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable, locally advanced, or metastatic human epidermal growth factor 2-positive",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}